Conmed (CNMD) Misses Q2 EPS by 8c, Maintains FY15 Guidance

Conmed (NASDAQ: CNMD) reported Q2 EPS of $0.36, $0.08 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $181 million versus the consensus estimate of $182.6 million.

2015 Outlook

The Company reiterated its previously disclosed constant currency sales guidance, which calls for organic sales growth in 2015 to be in the range of 1% to 3%. Using current exchange rates, CONMED continues to anticipate that reported sales for 2015 will be in the range of $723 million to $738 million, representing a growth range of (2%) to 0%, and that adjusted diluted net earnings per share will be in the range of $1.82 to $1.92.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Raymond James Reiterates Underperform Rating on Lennar (LEN)
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk